-

DexCom Promotes Jake Leach to Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the promotion of Jake Leach to the role of chief operating officer.

Leach has most recently served as chief technology officer at Dexcom since 2018, leading the organization’s research, product development, project management and engineering departments. An 18-year veteran of the company, Jake joined Dexcom in 2004 to lead the development of sensor electronics for the first commercial Dexcom CGM system. Since then, he has led the teams responsible for developing multiple generations of Dexcom CGM, including Dexcom G6, the best-selling real-time CGM in the world.

“For nearly two decades, Jake has helped lead technology development at Dexcom, ensuring our organization is on the forefront of innovation in continuous glucose monitoring and data connectivity,” said Kevin Sayer, chairman, president and chief executive officer at Dexcom. “In this new role, Jake will expand upon his proven leadership and industry expertise to ensure that Dexcom remains at the forefront of sensing technology and well-positioned to bring Dexcom CGM to the millions of additional people who stand to benefit from it.”

As chief operating officer, Leach will have end-to-end responsibility for product at Dexcom, driving day-to-day decision-making and resource allocation across all major product-facing groups. In addition, Jake will oversee several executive leadership functions, including global operations, research and development, quality management and regulatory, creating an integrated management structure that strengthens the company’s ability to execute on its vision for long-term sustainable growth.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

© 2022 Dexcom, Inc. Dexcom and Dexcom G6 are registered trademarks of DexCom, Inc. in the U.S., and may be registered in other countries. All rights reserved.

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:dxcm

Release Versions
$Cashtags
Hashtags

Contacts

Media Contact
James McIntosh
619-884-2118
james.mcintosh@dexcom.com

Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com

More News From DexCom, Inc.

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights...
Back to Newsroom